United States (US)
United Kingdom (GB)Routine eyes exams can now help to save lives
Join a growing community of forward-thinking optometrists who are supercharging their offering with AI-powered health assessments.
In partnership with
Now available
Coming soon to US
Real-time, non-invasive health assessments
Estimates a person’s biological age via vascular and metabolic indicators present in the retinal image, helping them to understand their overall health.
Now available
Performs real-time, non-invasive cardiovascular risk assessments using retinal imagery, along with basic info like age.
Coming soon to the US
-
CLAiR has Breakthrough Device status from the United States Food and Drug Administration (FDA) and is currently undergoing fast-tracked regulatory review.
CLAiR is expected to be available in United States in 2026, pending FDA clearance.
Register your interest to be the one of the first to know when it’s available in your region.
Detects elevated risk of chronic kidney disease in people with diabetes using retinal imagery.
Coming soon
These products have varying regulatory statuses depending on region and are not yet cleared for sale in all markets. Register your interest to learn which products are available in your region.
Why Optometrists Love BioAge
Simple Setup
Get set up online within minutes – no technical know-how required.
Online Reports
Patients get instant access to their results, along with educational material from the American Heart Association.
Improve
Retention
89%
who have a BioAge
test intend to return
again in 12 months
Increase
Revenue
⬆32%
Average increase in
ancillary revenue
from BioAge¹
Toku’s AI models have been developed using over
4,300,000
retinal images linked to medical records.
We never store or use patient data
to improve or train AI models.
Backed by Science
Increased BioAge results are proven to correlate with increased cardiovascular and metabolic risk factors like hypertension, diabetes and kidney disease.
Seamlessly integrated
with your existing patient workflows and retinal camera
Results return within
30
seconds
Committed to quality
We accept nothing less than the highest standards of quality and safety.
¹ During a 6-month pilot in California & Texas, optometrists offering BioAge saw a 32% increase in revenue from ancillary sales
How BioAge works
1. Capture
Capture images of the retina, along with a few details such as age and sex.
2. Analyze
BioAge uses AI and deep learning technology to analyze the retinal images and return results within 30 seconds.
3. Report
Clinicians can view the results in PDF format. Patients receive access to their results via a secure online portal.
How much extra revenue could you be making?
Calculate the revenue potential of BioAge for your practice using the calculator below.
Frequently Asked Questions
-
BioAge currently works with the following retinal cameras:
Topcon: Maestro 1, Maestro 2, NW400, NW500
Optos: California and Daytona
Using a different camera model? Register your interest to be notified when BioAge is supported with your hardware. -
If you’re in a supported region and using one of our approved retinal cameras, you can get started today! After signing up, you’ll receive step-by-step instructions to complete your setup, along with guidance on how to use BioAge and discuss results with your patients. Once setup is complete, we’ll activate your account within 24 hours.
If your retinal camera isn’t supported yet, we’ll let you know as soon as it is. We’re continuously expanding our compatibility based on demand.
If you’re located in a region we don’t currently support, we’ll be in touch as soon as we launch there.
-
BioAge is a test that uses AI software technology on images of the retina to estimate a person’s biological age, helping them to understand and take charge of their overall health. See our research to learn more.
-
The BioAge software has no associated risks. As part of the BioAge process, patients will need to have fundus images taken using a retinal camera.
-
BioAge has only been designed for people between the ages of 35-75.
Currently, BioAge is not designed for individuals who have had a previous cardiac event or with persistent vision impairment, monocular vision, congenital eye disease, history of significant ocular trauma, pathological myopia or those who are pregnant.
-
Patients should be recommended to do an assessment every year.
-
What you charge for BioAge is entirely up to you. Pricing can vary based on your practice, patient base, and local market.
We recommend offering BioAge as part of a bundled package with retinal imaging, rather than as a separate upsell. This approach keeps the experience seamless for patients and supports broader adoption — while still enabling your practice to generate additional revenue.
If you’re unsure where to start, many practices find success by increasing the price of a comprehensive eye exam that includes retinal imaging and BioAge.
-
Register your interest to receive access to the Discovery Center, where you can learn about pricing.
-
CLAiR has been granted Breakthrough Device status by the U.S. FDA and is currently undergoing fast-tracked regulatory review. It will be made available in the US once approved. We expect this to be some time in 2026.
Register your interest to be the first to know when it’s available in your region.
-
The BioAge report is not intended to be used for medical decisions or to replace professional medical advice.
When someone receives their BioAge results online, they’ll have the option to schedule an appointment with a nearby health and wellbeing partner.
-
The BioAge result is usually returned within 20-40 seconds of pressing the button. The whole BioAge process adds less than three minutes onto appointment times.
Adopt the latest Optometry Tech
– Healthcare from the Eye
You’ll receive a no-obligation information pack and an opportunity to secure your spot on the waitlist.